Literature DB >> 10698967

Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter.

C G Lee1, M Ramachandra, K T Jeang, M A Martin, I Pastan, M M Gottesman.   

Abstract

The MDR1 multidrug transporter P-gp (P-glycoprotein) is an efflux pump that extrudes diverse hydrophobic drugs and peptides from cells. Since the entry of HIV-1 into cells involves an initial interaction of the viral gp41 hydrophobic peptide with the plasma membrane, a potential effect of P-gp on HIV-1 infectivity was explored. Virus production was greatly decreased when P-gp was overexpressed at the surface of a continuous CD4(+) human T-leukemic cell line (12D7) infected with HIV-1(NL4-3), a T-tropic molecular clone of HIV-1. P-gp overexpression did not significantly alter the surface expression or distribution of either the HIV-1 receptor CD4 or the coreceptor CXCR4. Reduction of HIV-1 infectivity in P-gp-expressing cells occurred both during the fusion of viral and plasma membranes and at subsequent step(s) in the HIV-1 life cycle.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10698967     DOI: 10.1096/fasebj.14.3.516

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  17 in total

1.  Clinical Pharmacologic Considerations for HIV-1 Protease Inhibitors.

Authors:  Peter L. Anderson; Courtney V. Fletcher
Journal:  Curr Infect Dis Rep       Date:  2001-08       Impact factor: 3.725

Review 2.  P glycoprotein in human immunodeficiency virus type 1 infection and therapy.

Authors:  Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 3.  Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.

Authors:  Minlu Hu; Sravan Kumar Patel; Tian Zhou; Lisa C Rohan
Journal:  J Control Release       Date:  2015-08-13       Impact factor: 9.776

4.  Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity.

Authors:  Soichi Haraguchi; Sarah K Ho; Matthew Morrow; Maureen M Goodenow; John W Sleasman
Journal:  J Leukoc Biol       Date:  2011-04-19       Impact factor: 4.962

Review 5.  Updated clinical pharmacologic considerations for HIV-1 protease inhibitors.

Authors:  Peter L Anderson; Courtney V Fletcher
Journal:  Curr HIV/AIDS Rep       Date:  2004-04       Impact factor: 5.071

6.  Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors.

Authors:  Todd Hulgan; John P Donahue; Laura Smeaton; Minya Pu; Hongying Wang; Michael M Lederman; Kimberly Smith; Hernan Valdez; Christopher Pilcher; David W Haas
Journal:  Eur J Clin Pharmacol       Date:  2009-11       Impact factor: 2.953

7.  Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells.

Authors:  Antonio Valentin; Matthew Morrow; Richard H Poirier; Karen Aleman; Richard Little; Robert Yarchoan; George N Pavlakis
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

8.  Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4.

Authors:  Andrew Owen; Becky Chandler; Patrick G Bray; Stephen A Ward; C Anthony Hart; David J Back; Saye H Khoo
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

9.  Comparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIV-negative populations.

Authors:  Rebekah L Benish; Benigno Rodriguez; Peter A Zimmerman; Rajeev K Mehlotra
Journal:  Infect Genet Evol       Date:  2009-10-09       Impact factor: 3.342

Review 10.  HIV and viral protein effects on the blood brain barrier.

Authors:  MaryPeace McRae
Journal:  Tissue Barriers       Date:  2016-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.